Structural and Dynamic Elucidation of a Non-acid PPARgammaPartial Agonist: SR1988.Frkic, R.L., Chua, B.S., Shin, Y., Pascal, B.D., Novick, S.J., Kamenecka, T.M., Griffin, P.R., Bruning, J.B.
(2018) Nucl Receptor Res 5
- PubMed: 30906767
- DOI: 10.11131/2018/101350
- Primary Citation of Related Structures:
- PubMed Abstract:
Targeting peroxisome proliferator-activated receptor γ (PPAR γ ) by synthetic compounds has been shown to elicit insulin sensitising properties in type 2 diabetics. Treatment with a class of these compounds, the thiazolidinediones (TZ ...
Targeting peroxisome proliferator-activated receptor γ (PPAR γ ) by synthetic compounds has been shown to elicit insulin sensitising properties in type 2 diabetics. Treatment with a class of these compounds, the thiazolidinediones (TZDs), has shown adverse side effects such as weight gain, fluid retention, and congestive heart failure. This is due to their full agonist properties on the receptor, where a number of genes are upregulated beyond normal physiological levels. Lessened transactivation of PPAR γ by partial agonists has proved beneficial in terms of reducing side effects, while still maintaining insulin sensitising properties. However, some partial agonists have been associated with unfavourable pharmacokinetic profiles due to their acidic moieties, often causing partitioning to the liver. Here we present SR1988, a new partial agonist with favourable non-acid chemical properties. We used a combination of X-ray crystallography and hydrogen/deuterium exchange (HDX) to elucidate the structural basis for reduced activation of PPAR γ by SR1988. This structural analysis reveals a mechanism that decreases stabilisation of the AF2 coactivator binding surface by the ligand.
Institute for Photonics and Advanced Sensing (IPAS), School of Biological Sciences, The University of Adelaide, Adelaide, South Australia 5005, Australia.